Shots:
- Xbrane Biopharma and JOINN Biologics have entered a strategic partnership to provide customized development services for Xdarzane, a biosimilar version of Darzalex (daratumumab)
- Under the agreement, JOINN will advance Xdarzane through pilot-scale process development, analytical similarity studies, and process optimization for commercial manufacturing. Xbrane will lead global out-licensing efforts, while both companies will collaborate on further development, scale-up, clinical studies, regulatory filings, and commercialization
- The partnership enables Xbrane to progress the program without additional direct development investment while combining Xbrane’s biosimilar expertise with JOINN’s biologics development and manufacturing capabilities
Ref: Xbrane Biopharma | Image: Xbrane Biopharma and JOINN Biologics | Press Release
Related News: Alvotech Reports US FDA BLA Acceptance of AVT16 (Biosimilar, Entyvio)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
